DB:I9DN

Stock Analysis Report

Executive Summary

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Arbutus Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: I9DN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.3%

I9DN

-11.1%

DE Biotechs

-9.1%

DE Market


1 Year Return

-32.1%

I9DN

-2.9%

DE Biotechs

2.9%

DE Market

Return vs Industry: I9DN underperformed the German Biotechs industry which returned -2.9% over the past year.

Return vs Market: I9DN underperformed the German Market which returned 2.9% over the past year.


Shareholder returns

I9DNIndustryMarket
7 Day-14.3%-11.1%-9.1%
30 Day4.2%-12.8%-7.2%
90 Day76.2%-9.6%-6.5%
1 Year-32.1%-32.1%-2.7%-2.9%6.1%2.9%
3 Year5.0%5.0%25.8%24.4%3.5%-5.6%
5 Year-85.7%-85.7%1.6%-0.5%8.0%-6.8%

Price Volatility Vs. Market

How volatile is Arbutus Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Arbutus Biopharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Arbutus Biopharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Arbutus Biopharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Arbutus Biopharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

11.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: I9DN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: I9DN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: I9DN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: I9DN's revenue (60.7% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: I9DN's revenue (60.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if I9DN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arbutus Biopharma performed over the past 5 years?

-9.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: I9DN is currently unprofitable.

Growing Profit Margin: I9DN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: I9DN is unprofitable, and losses have increased over the past 5 years at a rate of -9.3% per year.

Accelerating Growth: Unable to compare I9DN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: I9DN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: I9DN has a negative Return on Equity (-176.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Arbutus Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: I9DN's short term assets ($94.3M) exceed its short term liabilities ($8.8M).

Long Term Liabilities: I9DN's short term assets ($94.3M) exceed its long term liabilities ($24.8M).


Debt to Equity History and Analysis

Debt Level: I9DN is debt free.

Reducing Debt: I9DN had no debt 5 years ago.


Balance Sheet

Inventory Level: I9DN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if I9DN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: I9DN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: I9DN has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -27.7% each year.


Next Steps

Dividend

What is Arbutus Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.9%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate I9DN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate I9DN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if I9DN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if I9DN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of I9DN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Bill Collier 0

0.7yrs

Tenure

0

Mr. William H. Collier has experience as a senior executive in the pharmaceutical industry and previously served as President and General Manager, North America at ViiV Healthcare. At ViiV he led the indus ...


Leadership Team

NamePositionTenureCompensationOwnership
David Hastings
CFO & Chief Accounting Officer1.7yrsUS$1.45mno data
Gaston Picchio
Chief Development Officer1.3yrsUS$1.78mno data
William Collier
President0.7yrsno datano data
Michael Sofia
Chief Scientific Officer5.1yrsUS$846.83k2.69% $4.7m
Pam Murphy
Investor Relations Consultant0yrsno datano data
Elizabeth Howard
Executive VP3.9yrsUS$740.05kno data
Michael McElhaugh
Chief Business Officer1.2yrsno data2.23% $3.9m
R. Mackay-Dunn
Secretary9.8yrsno datano data

1.7yrs

Average Tenure

59.5yo

Average Age

Experienced Management: I9DN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
William Collier
President0.7yrsno datano data
Richard Henriques
Independent Non-Executive Director4.9yrsUS$188.23k0.0016% $2.8k
Daniel Burgess
Independent Director2.9yrsUS$180.23kno data
Keith Manchester
Independent Non-Executive Director4.9yrsUS$157.72k0.18% $321.1k
Adrian Di Bisceglie
Member of Scientific Advisory Board0yrsno datano data
Charles Rice
Member of Scientific Advisory Board0yrsno datano data
James Meyers
Independent Director1.3yrsUS$170.96kno data
William Symonds
Chairman of Scientific Advisory Board1.3yrsno datano data
Frank Torti
Independent Chairman of the Board of Directors1.3yrsUS$162.35kno data
Scott Biller
Member of Scientific Advisory Board0yrsno datano data

1.3yrs

Average Tenure

54yo

Average Age

Experienced Board: I9DN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Arbutus Biopharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arbutus Biopharma Corporation
  • Ticker: I9DN
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$192.547m
  • Listing Market Cap: US$175.083m
  • Shares outstanding: 62.11m
  • Website: https://www.arbutusbio.com

Number of Employees


Location

  • Arbutus Biopharma Corporation
  • 701 Veterans Circle
  • Warminster
  • Pennsylvania
  • 18974
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABUSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDMay 2007
I9DNDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2007

Biography

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. The company develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer AB-452, an orally administered agent, in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and to reduction in HBsAg levels. In addition, it engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with SOC therapies, and in combination with each other. The company has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Acuitas Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Monsanto Company; Marina Biotech, Inc.; and Arcturus Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/28 21:49
End of Day Share Price2020/02/28 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.